Building On Bayer

Onyx has learned a lot in its almost twenty year history with Bayer, managing through the upside and downside of having a Big Pharma partner.

Until last year, for Wall Street, the Onyx Pharmaceuticals Inc. story was all about Nexavar (sorafenib), the drug that Onyx partnered with Bayer AG in 1994. [See Deal] FDA approved Nexavar for advanced kidney cancer in 2005 and for unresectable liver cancer in 2007.

The drug is clearly a blockbuster, with more than $1 billion in total sales globally in 2012. Onyx revenue from the Nexavar collaboration was $288 million. After accounting for foreign...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo